SUPPLEMENT

Q1 2022 — Sales of Key Products/Franchises

Q1 2022PDF · 7 pages166 KB
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC (5)
US 670	$ 599 11.8% 11.8% -
Intl 791 673 17.5% 21.7% -4.2%
WW 1,461 1,273 14.8% 17.1% -2.3%
SKIN HEALTH / BEAUTY
US 544 634 -14.2% -14.2% -
Intl 468 529 -11.6% -7.1% -4.5%
WW 1,012 1,163 -13.0% -11.0% -2.0%
ORAL CARE
US 143 163 -12.6% -12.6% -
Intl 223 254 -12.0% -8.6% -3.4%
WW 366 417 -12.2% -10.2% -2.0%
BABY CARE
US 85 96 -11.5% -11.5% -
Intl 270 293 -7.7% -4.8% -2.9%
WW 355 389 -8.6% -6.4% -2.2%
WOMEN'S HEALTH
US 3 3 7.2% 7.2% -
Intl 224 219 2.5% 8.3% -5.8%
WW 228 222 2.6% 8.3% -5.7%
WOUND CARE / OTHER
US 112 115 -3.3% -3.3% -
Intl 52 61 -15.3% -14.5% -0.8%
WW 164 177 -7.4% -7.2% -0.2%
TOTAL CONSUMER HEALTH
US 1,557 1,611 -3.4% -3.4% -
Intl 2,029 2,030 0.0% 4.1% -4.1%
WW 3,586	$ 3,641 -1.5% 0.8% -2.3%
See footnotes at end of schedule
% Change

-- 1 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency
IMMUNOLOGY
US 2,501	$ 2,413 3.7% 3.7% -
Intl 1,617 1,501 7.7% 13.7% -6.0%
WW 4,119 3,914 5.2% 7.5% -2.3%
REMICADE
US 358 489 -26.8% -26.8% -
US Exports (4) 80 57 40.5% 40.5% -
Intl 225 232 -2.6% -1.0% -1.6%
WW 663 777 -14.7% -14.2% -0.5%
SIMPONI / SIMPONI ARIA
US 287 255 12.5% 12.5% -
Intl 283 307 -7.6% -1.9% -5.7%
WW 571 562 1.5% 4.7% -3.2%
STELARA
US 1,379 1,331 3.6% 3.6% -
Intl 909 817 11.2% 17.8% -6.6%
WW 2,288 2,148 6.5% 9.0% -2.5%
TREMFYA
US 391 274 42.7% 42.7% -
Intl 199 143 38.8% 47.9% -9.1%
WW 590 418 41.3% 44.5% -3.2%
OTHER IMMUNOLOGY
US 6 7 -3.2% -3.2% -
Intl 0 2 * * *
WW 6 8 -22.0% -22.0% -
INFECTIOUS DISEASES (5)
US 461 512 -10.0% -10.0% -
Intl 836 485 72.3% 78.6% -6.3%
WW 1,297 998 30.0% 33.1% -3.1%
COVID-19 VACCINE
US 75 100 -24.9% -24.9% -
Intl 382 0 * * *
WW 457 100 * * *
EDURANT / rilpivirine
US 9 10 -12.6% -12.6% -
Intl 239 233 2.5% 10.5% -8.0%
WW 248 243 1.8% 9.6% -7.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 369 380 -3.1% -3.1% -
Intl 132 166 -20.3% -15.9% -4.4%
WW 501 546 -8.3% -6.9% -1.4%
OTHER INFECTIOUS DISEASES
US 8 21 -62.5% -62.5% -
Intl 83 87 -3.8% 1.6% -5.4%
WW 91 108 -15.3% -11.0% -4.3%
% Change

-- 2 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
NEUROSCIENCE (5)
US 843 771 9.3% 9.3% -
Intl 898 943 -4.8% 1.5% -6.3%
WW 1,741 1,715 1.5% 5.0% -3.5%
CONCERTA / Methylphenidate
US 35 47 -26.5% -26.5% -
Intl 122 123 -1.3% 3.5% -4.8%
WW 157 171 -8.3% -4.8% -3.5%	INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 661 589 12.2% 12.2% -
Intl 387 376 3.0% 9.9% -6.9%
WW 1,048 965 8.6% 11.3% -2.7%
RISPERDAL CONSTA
US 63 67 -6.4% -6.4% -
Intl 66 89 -26.1% -19.6% -6.5%
WW 129 157 -17.6% -13.9% -3.7%
OTHER NEUROSCIENCE
US 84 67 25.5% 25.5% -
Intl 323 355 -8.9% -2.8% -6.1%
WW 408 422 -3.5% 1.7% -5.2%
ONCOLOGY
US 1,582 1,377 14.9% 14.9% -
Intl 2,369 2,193 8.0% 15.0% -7.0%
WW 3,950 3,570 10.6% 14.9% -4.3%
DARZALEX
US 953 691 37.9% 37.9% -
Intl 903 674 34.0% 42.7% -8.7%
WW 1,856 1,365 36.0% 40.3% -4.3%
ERLEADA
US 206 171 20.3% 20.3% -
Intl 194 90 * * *
WW 400 261 53.0% 57.5% -4.5%
IMBRUVICA
US 370 444 -16.7% -16.7% -
Intl 668 680 -1.8% 4.5% -6.3%
WW 1,038 1,125 -7.7% -3.9% -3.8%
ZYTIGA / abiraterone acetate
US 19 50 -62.1% -62.1% -
Intl 520 588 -11.6% -5.7% -5.9%
WW 539 638 -15.6% -10.1% -5.5%
OTHER ONCOLOGY
US 34 21 63.1% 63.1% -
Intl 84 161 -47.7% -44.6% -3.1%
WW 118 182 -35.1% -32.3% -2.8%
% Change

-- 3 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 572 573 -0.2% -0.2% -
Intl 279 288 -2.9% 4.0% -6.9%
WW 852 861 -1.1% 1.2% -2.3%
OPSUMIT
US 273 272 0.5% 0.5% -
Intl 170 179 -4.8% 2.0% -6.8%
WW 443 450 -1.6% 1.1% -2.7%
UPTRAVI
US 269 259 3.9% 3.9% -
Intl 56 46 20.9% 28.8% -7.9%
WW 325 305 6.5% 7.7% -1.2%
OTHER PULMONARY HYPERTENSION
US 30 42 -29.0% -29.0% -
Intl 53 63 -15.2% -8.4% -6.8%
WW 83 105 -20.8% -16.8% -4.0%
CARDIOVASCULAR / METABOLISM / OTHER (5)
US 672 799 -15.8% -15.8% -
Intl 238 245 -3.0% 0.9% -3.9%
WW 910 1,044 -12.8% -11.9% -0.9%
XARELTO
US 508 589 -13.8% -13.8% -
Intl - - - - -
WW 508 589 -13.8% -13.8% -
INVOKANA / INVOKAMET
US 60 87 -30.7% -30.7% -
Intl 68 63 7.5% 11.1% -3.6%
WW 128 150 -14.6% -13.1% -1.5%
OTHER
US 104 122 -14.9% -14.9% -
Intl 170 182 -6.6% -2.6% -4.0%
WW 274 305 -10.0% -7.5% -2.5%
TOTAL PHARMACEUTICAL
US 6,632 6,446 2.9% 2.9% -
Intl 6,237 5,655 10.3% 16.7% -6.4%
WW 12,869	$ 12,101 6.3% 9.3% -3.0%
See footnotes at end of schedule
% Change

-- 4 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2,3,6) 2022 2021 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 494	$ 434 13.8% 13.8% -
Intl 597 514 16.2% 20.4% -4.2%
WW 1,092 949 15.1% 17.4% -2.3%
ORTHOPAEDICS
US 1,289 1,249 3.2% 3.2% -
Intl 899 864 4.1% 9.1% -5.0%
WW 2,188 2,113 3.5% 5.6% -2.1%
HIPS
US 225 209 7.3% 7.3% -
Intl 164 146 12.2% 17.0% -4.8%
WW 389 356 9.3% 11.3% -2.0%
KNEES
US 201 185 8.6% 8.6% -
Intl 138 132 4.1% 9.1% -5.0%
WW 339 317 6.7% 8.8% -2.1%
TRAUMA
US 475 450 5.5% 5.5% -
Intl 273 282 -3.3% 2.2% -5.5%
WW 748 733 2.1% 4.2% -2.1%
SPINE, SPORTS & OTHER
US 387 404 -4.1% -4.1% -
Intl 324 303 7.0% 11.7% -4.7%
WW 712 707 0.6% 2.7% -2.1%
% Change

-- 5 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
SURGERY
US 921 898 2.5% 2.5% -
Intl 1,513 1,474 2.7% 6.6% -3.9%
WW 2,434 2,372 2.6% 5.0% -2.4%
ADVANCED
US 417 405 3.0% 3.0% -
Intl 729 713 2.2% 5.4% -3.2%
WW 1,146 1,118 2.5% 4.5% -2.0%
GENERAL
US 504 493 2.1% 2.1% -
Intl 784 761 3.1% 7.7% -4.6%
WW 1,288 1,254 2.7% 5.5% -2.8%
VISION
US 521 472 10.4% 10.4% -
Intl 736 673 9.4% 16.4% -7.0%
WW 1,257 1,145 9.8% 13.9% -4.1%
CONTACT LENSES / OTHER
US 400 371 7.7% 7.7% -
Intl 511 486 5.1% 12.9% -7.8%
WW 910 857 6.2% 10.6% -4.4%
SURGICAL
US 121 101 20.2% 20.2% -
Intl 226 187 20.5% 25.7% -5.2%
WW 347 288 20.4% 23.8% -3.4%
TOTAL MEDTECH
US 3,225 3,054 5.6% 5.6% -
Intl 3,746 3,525 6.3% 11.1% -4.8%
WW 6,971	$ 6,579 5.9% 8.5% -2.6%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(6) Previously referred to as Medical Devices
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
(5) Refer to supplemental sales information schedule
% Change

-- 6 of 7 --

Full Year Q1 Q2 Q3 Q4 Full Year
CONSUMER HEALTH SEGMENT (1)
OTC (2)
US 2,460 599 675 686 633 2,594
Intl 2,761 673 752 798 811 3,034
WW 5,221 1,273 1,426 1,484 1,444 5,627
PHARMACEUTICAL SEGMENT (1)
INFECTIOUS DISEASES (2)
OTHER INFECTIOUS DISEASES
US 104 21 16 18 11 66
Intl 292 87 71 82 57 297
WW 396 108 88 99 68 363
NEUROSCIENCE (2)
OTHER NEUROSCIENCE
US 298 67 91 81 99 338
Intl 1,312 355 373 298 342 1,368
WW 1,610 422 464 379 441 1,706
CARDIOVASCULAR / METABOLISM / OTHER (2,3)
OTHER
US 600 122 116 98 110 446
Intl 794 182 178 173 140 673
WW 1,394 305 293 271 250 1,119
Note: Columns and rows within tables may not add due to rounding
(1) Unaudited
(3) Other is inclusive of PROCRIT / EPREX, which was previously disclosed separately
(2) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment
based on operational changes in their respective regions
Supplemental Sales Information
(Dollars in Millions)
Certain prior year amounts have been reclassified to
conform to current year product disclosures
2020 2021 2021

-- 7 of 7 --